♥
ISIN : INE485C01011
NSE : IOLCP
BSE : 524164
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 22.90
EPS (TTM) : 20.20
Price to Earning (P/E) : 2.67
Book Value : 274.49
Price to Bookvalue (P/B) : 0.22
Dividend Yield : 7 %
Return on Equity (ROE) : 8.62 %
Return on Capital Employed (ROCE) : 12.24 %
IOL Chemicals and Pharmaceuticals Limited
ISIN : INE485C01011
NSE : IOLCP
BSE : 524164
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 22.90
EPS (TTM) : 20.20
Price to Earning (P/E) : 2.67
Book Value : 274.49
Price to Bookvalue (P/B) : 0.22
Dividend Yield : 7 %
Return on Equity (ROE) : 8.62 %
Return on Capital Employed (ROCE) : 12.24 %
IOL Chemicals share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 75.92 - 77.34 1.9 % |
| Low / High | 73.8 - 77.66 5.2 % |
| Trade Volume | 60,568 |
| 52 Week Low / High | 60.55 - 126.6 109.1 % |
-
YOU MAY ALSO LIKE
- Stock market course tutorial
Stock Market Investment Course explained in simple words. - Share Market basics for beginners
Share Market jargons in simple terms - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CONSOLIDATED QUARTERLY RESULT FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 5724.9 | 5650.1 | 5414.1 | 5234.8 | 5872.1 | 5631.8 | 5453 | 5203.9 | 5039.2 | 5023.8 |
| Total Income | 5794.2 | 5701.7 | 5464.8 | 5301.3 | 5959.4 | 5702.4 | 5524.1 | 5287.7 | 5114.4 | 5097.6 |
| Total Expenditure | 5273.6 | 5092.2 | 5095.1 | 4807.9 | 4919.1 | 4906.6 | 4811 | 4760.4 | 4544 | 4512.7 |
| Other Income | 69.3 | 51.6 | 50.7 | 66.5 | 87.3 | 70.6 | 71.1 | 83.8 | 75.2 | 73.8 |
| Operating Profit | 520.6 | 609.5 | 369.7 | 493.4 | 1040.3 | 795.8 | 713.1 | 527.3 | 570.4 | 584.9 |
| Interest | 23.4 | 33.8 | 35.1 | 47 | 48.8 | 39.5 | 44.4 | 43 | 34.1 | 21.5 |
| PBDT | 497.2 | 575.7 | 334.6 | 446.4 | 991.5 | 756.3 | 668.7 | 484.3 | 536.3 | 563.4 |
| Depreciation | 110.1 | 109.8 | 113.2 | 117.5 | 121.1 | 144.5 | 156.9 | 163.4 | 164.3 | 168.2 |
| Profit Before Tax | 387.1 | 465.9 | 221.4 | 328.9 | 870.4 | 611.8 | 511.8 | 320.9 | 372 | 395.2 |
| Tax | 89.5 | 119.2 | 62.3 | 91 | 222.6 | 153.2 | 133.1 | 90.1 | 95.8 | 95.5 |
| Profit After Tax | 297.6 | 346.7 | 159.1 | 237.9 | 647.8 | 458.6 | 378.7 | 230.8 | 276.2 | 299.7 |
| Net Profit | 297.6 | 346.7 | 159.1 | 237.9 | 647.8 | 458.6 | 378.7 | 230.8 | 276.2 | 299.7 |
| Equity Capital | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 13335.7 | 13677.8 | 13833.6 | 14069.5 | 14490.1 | 14936.4 | 15310.3 | 15542.2 | 15528 | 15813.4 |
| Calculated EPS | 5.07 | 5.91 | 2.71 | 4.05 | 11.03 | 7.81 | 6.45 | 3.93 | 4.7 | 5.1 |
| Diluted Eps After Extraordinary Items | 5.07 | 5.91 | 2.71 | 4.05 | 11.03 | 7.81 | 6.45 | 3.93 | 4.71 | 5.11 |
| Diluted Eps Before Extraordinary Items | 5.07 | 5.91 | 2.71 | 4.05 | 11.03 | 7.81 | 6.45 | 3.93 | 4.71 | 5.11 |
STANDALONE QUARTERLY RESULT FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 5724.9 | 5650.1 | 5414.1 | 5234.8 | 5872.1 | 5631.8 | 5453 | 5203.9 | 5039.2 | 5023.8 |
| Total Income | 5794.2 | 5701.6 | 5464.7 | 5301.2 | 5959.3 | 5702.4 | 5524.1 | 5287.7 | 5114.4 | 5097.6 |
| Total Expenditure | 5293.7 | 5089.9 | 5097.4 | 4804.4 | 4914.2 | 4903.2 | 4812 | 4759.1 | 4538.4 | 4515.8 |
| Other Income | 69.3 | 51.5 | 50.6 | 66.4 | 87.2 | 70.6 | 71.1 | 83.8 | 75.2 | 73.8 |
| Operating Profit | 500.5 | 611.7 | 367.3 | 496.8 | 1045.1 | 799.2 | 712.1 | 528.6 | 576 | 581.8 |
| Interest | 23.4 | 33.8 | 35.1 | 47 | 48.8 | 39.5 | 44.4 | 43 | 34.1 | 21.5 |
| PBDT | 477.1 | 577.9 | 332.2 | 449.8 | 996.3 | 759.7 | 667.7 | 485.6 | 541.9 | 560.3 |
| Depreciation | 110.1 | 109.8 | 113.2 | 117.3 | 121 | 144.4 | 156.7 | 163.2 | 164.2 | 168 |
| Profit Before Tax | 367 | 468.1 | 219 | 332.5 | 875.3 | 615.3 | 511 | 322.4 | 377.7 | 392.3 |
| Tax | 89.5 | 119.2 | 62.3 | 91 | 222.6 | 153.2 | 133.1 | 90.1 | 95.8 | 95.5 |
| Profit After Tax | 277.5 | 348.9 | 156.7 | 241.5 | 652.7 | 462.1 | 377.9 | 232.3 | 281.9 | 296.8 |
| Net Profit | 277.5 | 348.9 | 156.7 | 241.5 | 652.7 | 462.1 | 377.9 | 232.3 | 281.9 | 296.8 |
| Equity Capital | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 | 587.1 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 13315.6 | 13659.9 | 13813.3 | 14052.8 | 14478.4 | 14928.2 | 15301.3 | 15534.7 | 15526.2 | 15808.7 |
| Calculated EPS | 4.73 | 5.94 | 2.67 | 4.11 | 11.12 | 7.87 | 6.44 | 3.96 | 4.8 | 5.06 |
| Diluted Eps After Extraordinary Items | 4.73 | 5.94 | 2.67 | 4.12 | 11.11 | 7.87 | 6.44 | 3.96 | 4.8 | 5.06 |
| Diluted Eps Before Extraordinary Items | 4.73 | 5.94 | 2.67 | 4.12 | 11.11 | 7.87 | 6.44 | 3.96 | 4.8 | 5.06 |
CONSOLIDATED ANNUAL RESULT FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 21840.2 | 22171.1 | 21327.9 |
| Total Income | 22160.6 | 22427.2 | 21628.6 |
| Total Expenditure | 19257.3 | 19914.4 | 19022 |
| Other Income | 320.4 | 256.1 | 300.7 |
| Operating Profit | 2903.3 | 2512.8 | 2606.6 |
| Interest | 82.9 | 164.7 | 161 |
| Exceptional Items | -139.3 | ||
| PBDT | 2681.1 | 2348.1 | 2445.6 |
| Depreciation | 432.6 | 461.6 | 629.1 |
| Profit Before Tax | 2248.5 | 1886.5 | 1816.5 |
| Tax | 571.8 | 495.1 | 472.2 |
| Profit After Tax | 1676.7 | 1391.4 | 1344.3 |
| Net Profit | 1676.7 | 1391.4 | 1344.3 |
| Equity Capital | 587.1 | 587.1 | 587.1 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | 13335.7 | 14490.1 | 15528 |
| Calculated EPS | 28.56 | 23.7 | 22.9 |
| Diluted Eps After Extraordinary Items | 28.56 | 23.7 | 22.9 |
| Diluted Eps Before Extraordinary Items | 28.56 | 23.7 | 22.9 |
STANDALONE ANNUAL RESULT FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 21840.2 | 22171.1 | 21327.9 |
| Total Income | 22160.6 | 22426.8 | 21628.6 |
| Total Expenditure | 19277.4 | 19905.9 | 19012.7 |
| Other Income | 320.4 | 255.7 | 300.7 |
| Operating Profit | 2883.2 | 2520.9 | 2615.9 |
| Interest | 82.9 | 164.7 | 161 |
| Exceptional Items | -139.3 | ||
| PBDT | 2661 | 2356.2 | 2454.9 |
| Depreciation | 432.6 | 461.3 | 628.5 |
| Profit Before Tax | 2228.4 | 1894.9 | 1826.4 |
| Tax | 571.8 | 495.1 | 472.2 |
| Profit After Tax | 1656.6 | 1399.8 | 1354.2 |
| Net Profit | 1656.6 | 1399.8 | 1354.2 |
| Equity Capital | 587.1 | 587.1 | 587.1 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | 13315.6 | 14478.4 | 15526.2 |
| Calculated EPS | 28.22 | 23.84 | 23.07 |
| Diluted Eps After Extraordinary Items | 28.22 | 23.84 | 23.07 |
| Diluted Eps Before Extraordinary Items | 28.22 | 23.84 | 23.07 |
CONSOLIDATED PROFIT / LOSS FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | months |
| Gross Sales | 2184.02 Cr | 2217.11 Cr | 2132.79 Cr | 0 |
| Sales | 2168.37 Cr | 2201.69 Cr | 2118.96 Cr | 0 |
| Net Sales | 2184.02 Cr | 2217.11 Cr | 2132.79 Cr | 0 |
| Increase/Decrease in Stock | -52.3 Cr | -18.2 Cr | -38.25 Cr | 0 |
| Raw Material Consumed | 1622.81 Cr | 1565.29 Cr | 1435.2 Cr | 0 |
| Opening Raw Materials | 181.75 Cr | 243.26 Cr | 134.08 Cr | 0 |
| Purchases Raw Materials | 1640.42 Cr | 1426.89 Cr | 1494.52 Cr | 0 |
| Closing Raw Materials | 243.26 Cr | 134.08 Cr | 193.55 Cr | 0 |
| Other Direct Purchases / Brought in cost | 43.9 Cr | 29.22 Cr | 15 Lk | 0 |
| Power & Fuel Cost | 78.18 Cr | 131.98 Cr | 149.05 Cr | 0 |
| Electricity & Power | 78.18 Cr | 131.98 Cr | 149.05 Cr | 0 |
| Employee Cost | 141.3 Cr | 168.21 Cr | 201.02 Cr | 0 |
| Salaries, Wages & Bonus | 125.28 Cr | 150.19 Cr | 179.09 Cr | 0 |
| Contributions to EPF & Pension Funds | 9.77 Cr | 11.2 Cr | 13.5 Cr | 0 |
| Workmen and Staff Welfare Expenses | 6.25 Cr | 6.82 Cr | 8.43 Cr | 0 |
| Other Manufacturing Expenses | 36.86 Cr | 43.07 Cr | 47.67 Cr | 0 |
| Repairs and Maintenance | 10.71 Cr | 13.45 Cr | 21.52 Cr | 0 |
| General and Administration Expenses | 5.12 Cr | 6.54 Cr | 9.01 Cr | 0 |
| Rent , Rates & Taxes | 62 Lk | 71 Lk | 2.32 Cr | 0 |
| Insurance | 4.25 Cr | 5.54 Cr | 6.4 Cr | 0 |
| Selling and Distribution Expenses | 66.84 Cr | 61.85 Cr | 51.25 Cr | 0 |
| Freight and Forwarding | 57.34 Cr | 49.65 Cr | 41.64 Cr | 0 |
| Miscellaneous Expenses | 26.92 Cr | 32.7 Cr | 47.25 Cr | 0 |
| Provision for doubtful debts | 1.27 Cr | 2 Lk | 24 Lk | 0 |
| Loss on disposal of fixed assets(net) | 1.09 Cr | 59 Lk | 4 Lk | 0 |
| Total Expenditure | 1925.73 Cr | 1991.44 Cr | 1902.2 Cr | 0 |
| Other Income | 32.04 Cr | 25.61 Cr | 30.07 Cr | 0 |
| Interest Received | 18.04 Cr | 16.73 Cr | 13.99 Cr | 0 |
| Profit on sale of Fixed Assets | 0 | 0 | 14 Lk | 0 |
| Provision Written Back | 3 Lk | 10 Lk | 16 Lk | 0 |
| Foreign Exchange Gains | 10.44 Cr | 7.06 Cr | 13.08 Cr | 0 |
| Operating Profit | 290.33 Cr | 251.28 Cr | 260.66 Cr | 0 |
| Interest | 8.29 Cr | 16.47 Cr | 16.1 Cr | 0 |
| Interest on Term Loan | 2.25 Cr | 10.62 Cr | 10.84 Cr | 0 |
| Bank Charges etc | 5.86 Cr | 5.78 Cr | 5.26 Cr | 0 |
| PBDT | 282.04 Cr | 234.81 Cr | 244.56 Cr | 0 |
| Depreciation | 43.26 Cr | 46.16 Cr | 62.91 Cr | 0 |
| Profit Before Taxation & Exceptional Items | 238.78 Cr | 188.65 Cr | 181.65 Cr | 0 |
| Exceptional Income / Expenses | -13.93 Cr | 0 | 0 | 0 |
| Profit Before Tax | 224.85 Cr | 188.65 Cr | 181.65 Cr | 0 |
| Provision for Tax | 57.18 Cr | 49.51 Cr | 47.22 Cr | 0 |
| Current Income Tax | 57.23 Cr | 44.94 Cr | 37.04 Cr | 0 |
| Deferred Tax | 17 Lk | 3.25 Cr | 10.21 Cr | 0 |
| Profit After Tax | 167.67 Cr | 139.14 Cr | 134.43 Cr | 0 |
| Consolidated Net Profit | 167.67 Cr | 139.14 Cr | 134.43 Cr | 0 |
| Profit Balance B/F | 971.31 Cr | 1103.76 Cr | 1219.4 Cr | 0 |
| Appropriations | 1138.98 Cr | 1242.9 Cr | 1353.83 Cr | 0 |
| Other Appropriation | 11.74 Cr | 2 Lk | 0 | 0 |
| Equity Dividend % | 40 | 40 | 50 | |
| Earnings Per Share | 28.56 | 23.7 | 22.9 | |
| Adjusted EPS | 28.56 | 23.7 | 22.9 |
STANDALONE PROFIT / LOSS FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 1966.98 Cr | 2184.02 Cr | 2217.11 Cr | 2132.79 Cr |
| Sales | 1946.14 Cr | 2168.37 Cr | 2201.69 Cr | 2118.96 Cr |
| Net Sales | 1966.98 Cr | 2184.02 Cr | 2217.11 Cr | 2132.79 Cr |
| Increase/Decrease in Stock | -17.11 Cr | -52.3 Cr | -18.2 Cr | -38.25 Cr |
| Raw Material Consumed | 1119.95 Cr | 1622.81 Cr | 1565.29 Cr | 1435.2 Cr |
| Opening Raw Materials | 100.19 Cr | 181.75 Cr | 243.26 Cr | 134.08 Cr |
| Purchases Raw Materials | 1201.51 Cr | 1640.42 Cr | 1426.89 Cr | 1494.52 Cr |
| Closing Raw Materials | 181.75 Cr | 243.26 Cr | 134.08 Cr | 193.55 Cr |
| Other Direct Purchases / Brought in cost | 0 | 43.9 Cr | 29.22 Cr | 15 Lk |
| Power & Fuel Cost | 51.46 Cr | 78.18 Cr | 131.98 Cr | 149.05 Cr |
| Electricity & Power | 51.46 Cr | 78.18 Cr | 131.98 Cr | 149.05 Cr |
| Employee Cost | 115.55 Cr | 141.3 Cr | 168.21 Cr | 201.02 Cr |
| Salaries, Wages & Bonus | 103.73 Cr | 125.28 Cr | 150.19 Cr | 179.09 Cr |
| Contributions to EPF & Pension Funds | 7.76 Cr | 9.77 Cr | 11.2 Cr | 13.5 Cr |
| Workmen and Staff Welfare Expenses | 4.06 Cr | 6.25 Cr | 6.82 Cr | 8.43 Cr |
| Other Manufacturing Expenses | 28.13 Cr | 36.86 Cr | 43.07 Cr | 47.67 Cr |
| Repairs and Maintenance | 6.8 Cr | 10.71 Cr | 13.45 Cr | 21.52 Cr |
| General and Administration Expenses | 4.48 Cr | 5.12 Cr | 6.52 Cr | 9 Cr |
| Rent , Rates & Taxes | 43 Lk | 62 Lk | 71 Lk | 2.32 Cr |
| Insurance | 3.73 Cr | 4.25 Cr | 5.54 Cr | 6.4 Cr |
| Selling and Distribution Expenses | 50.78 Cr | 66.84 Cr | 61.85 Cr | 51.25 Cr |
| Freight and Forwarding | 41.15 Cr | 57.34 Cr | 49.65 Cr | 41.64 Cr |
| Miscellaneous Expenses | 21.9 Cr | 28.93 Cr | 31.87 Cr | 46.33 Cr |
| Provision for doubtful debts | 0 | 1.27 Cr | 2 Lk | 24 Lk |
| Loss on disposal of fixed assets(net) | 15 Lk | 1.09 Cr | 59 Lk | 4 Lk |
| Total Expenditure | 1375.14 Cr | 1927.74 Cr | 1990.59 Cr | 1901.27 Cr |
| Other Income | 24.3 Cr | 32.04 Cr | 25.57 Cr | 30.07 Cr |
| Interest Received | 15.97 Cr | 18.04 Cr | 16.69 Cr | 13.99 Cr |
| Profit on sale of Fixed Assets | 5 Lk | 0 | 0 | 14 Lk |
| Profits on sale of Investments | 1 Lk | 0 | 0 | 0 |
| Provision Written Back | 51 Lk | 3 Lk | 10 Lk | 16 Lk |
| Foreign Exchange Gains | 6.91 Cr | 10.44 Cr | 7.06 Cr | 13.08 Cr |
| Operating Profit | 616.14 Cr | 288.32 Cr | 252.09 Cr | 261.59 Cr |
| Interest | 5.83 Cr | 8.29 Cr | 16.47 Cr | 16.1 Cr |
| Interest on Term Loan | 59 Lk | 2.25 Cr | 4.11 Cr | 10.84 Cr |
| Bank Charges etc | 4.89 Cr | 5.86 Cr | 5.78 Cr | 5.26 Cr |
| PBDT | 610.31 Cr | 280.03 Cr | 235.62 Cr | 245.49 Cr |
| Depreciation | 38.92 Cr | 43.26 Cr | 46.13 Cr | 62.85 Cr |
| Profit Before Taxation & Exceptional Items | 571.39 Cr | 236.77 Cr | 189.49 Cr | 182.64 Cr |
| Exceptional Income / Expenses | 0 | -13.93 Cr | 0 | 0 |
| Profit Before Tax | 571.39 Cr | 222.84 Cr | 189.49 Cr | 182.64 Cr |
| Provision for Tax | 126.83 Cr | 57.18 Cr | 49.51 Cr | 47.22 Cr |
| Current Income Tax | 145.18 Cr | 57.23 Cr | 44.94 Cr | 37.04 Cr |
| Deferred Tax | -18.72 Cr | 17 Lk | 3.25 Cr | 10.21 Cr |
| Profit After Tax | 444.56 Cr | 165.66 Cr | 139.98 Cr | 135.42 Cr |
| Consolidated Net Profit | 444.56 Cr | 165.66 Cr | 139.98 Cr | 135.42 Cr |
| Profit Balance B/F | 550.23 Cr | 971.31 Cr | 1101.75 Cr | 1218.23 Cr |
| Appropriations | 994.79 Cr | 1136.97 Cr | 1241.73 Cr | 1353.65 Cr |
| Other Appropriation | 0 | 11.74 Cr | 2 Lk | 0 |
| Equity Dividend % | 60 | 40 | 40 | 50 |
| Earnings Per Share | 75.72 | 28.22 | 23.84 | 23.07 |
| Adjusted EPS | 75.72 | 28.22 | 23.84 | 23.07 |
CONSOLIDATED CASH FLOW FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Year End | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | months |
| Profit Before Tax | 224.85 Cr | 188.65 Cr | 181.65 Cr | 0 |
| Adjustment | 33.12 Cr | 44.41 Cr | 60.12 Cr | 0 |
| Changes In working Capital | -102.34 Cr | -63.69 Cr | 90.33 Cr | 0 |
| Cash Flow after changes in Working Capital | 155.63 Cr | 169.37 Cr | 332.1 Cr | 0 |
| Cash Flow from Operating Activities | 93.05 Cr | 122.27 Cr | 290.08 Cr | 0 |
| Cash Flow from Investing Activities | -120.19 Cr | -120 Cr | -191.28 Cr | 0 |
| Cash Flow from Financing Activitie | -1.64 Cr | -4.11 Cr | -92.5 Cr | 0 |
| Net Cash Inflow / Outflow | -28.78 Cr | -1.84 Cr | 6.3 Cr | 0 |
| Opening Cash & Cash Equivalents | 32.34 Cr | 3.23 Cr | 1.39 Cr | 0 |
| Closing Cash & Cash Equivalent | 3.56 Cr | 1.39 Cr | 7.69 Cr | 0 |
STANDALONE CASH FLOW FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 571.39 Cr | 222.84 Cr | 189.49 Cr | 182.64 Cr |
| Adjustment | 27.15 Cr | 33.12 Cr | 44.42 Cr | 60.06 Cr |
| Changes In working Capital | -76.51 Cr | -102.34 Cr | -63.67 Cr | 90.08 Cr |
| Cash Flow after changes in Working Capital | 522.03 Cr | 153.62 Cr | 170.24 Cr | 332.78 Cr |
| Cash Flow from Operating Activities | 379.78 Cr | 91.04 Cr | 123.14 Cr | 290.76 Cr |
| Cash Flow from Investing Activities | -317.25 Cr | -120.29 Cr | -119.19 Cr | -191.69 Cr |
| Cash Flow from Financing Activitie | -58.28 Cr | -1.64 Cr | -4.11 Cr | -92.5 Cr |
| Net Cash Inflow / Outflow | 4.25 Cr | -30.89 Cr | -16 Lk | 6.57 Cr |
| Opening Cash & Cash Equivalents | 28.09 Cr | 32.34 Cr | 1.12 Cr | 96 Lk |
| Closing Cash & Cash Equivalent | 32.34 Cr | 1.45 Cr | 96 Lk | 7.53 Cr |
CONSOLIDATED BALANCE SHEET FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Share Capital | 58.71 Cr | 58.71 Cr | 58.71 Cr | 0 |
| Equity - Authorised | 80 Cr | 80 Cr | 80 Cr | 0 |
| Equity - Issued | 58.71 Cr | 58.71 Cr | 58.71 Cr | 0 |
| Equity Paid Up | 58.71 Cr | 58.71 Cr | 58.71 Cr | 0 |
| Face Value | 10 | 10 | 10 | |
| Total Reserves | 1333.57 Cr | 1449.01 Cr | 1552.8 Cr | 0 |
| Securities Premium | 225.72 Cr | 225.72 Cr | 225.72 Cr | 0 |
| Capital Reserves | 10.76 Cr | 10.76 Cr | 10.76 Cr | 0 |
| Profit & Loss Account Balance | 1103.76 Cr | 1219.4 Cr | 1324.48 Cr | 0 |
| Reserve excluding Revaluation Reserve | 1333.57 Cr | 1449.01 Cr | 1552.8 Cr | 0 |
| Shareholder's Funds | 1392.28 Cr | 1507.72 Cr | 1611.51 Cr | 0 |
| Deferred Tax Assets / Liabilities | 53.18 Cr | 56.36 Cr | 66.14 Cr | 0 |
| Deferred Tax Assets | 2.91 Cr | 3.97 Cr | 4.56 Cr | 0 |
| Deferred Tax Liability | 56.09 Cr | 60.33 Cr | 70.7 Cr | 0 |
| Other Long Term Liabilities | 43 Lk | 14 Lk | 4 Lk | 0 |
| Long Term Provisions | 3.01 Cr | 1.65 Cr | 6.71 Cr | 0 |
| Total Non-Current Liabilities | 56.62 Cr | 58.15 Cr | 72.89 Cr | 0 |
| Trade Payables | 409.29 Cr | 314.22 Cr | 469.18 Cr | 0 |
| Sundry Creditors | 409.29 Cr | 314.22 Cr | 469.18 Cr | 0 |
| Other Current Liabilities | 54.02 Cr | 54.28 Cr | 54.67 Cr | 0 |
| Advances received from customers | 14.07 Cr | 7.44 Cr | 8.85 Cr | 0 |
| Short Term Borrowings | 42.75 Cr | 79.63 Cr | 32.76 Cr | 0 |
| Secured ST Loans repayable on Demands | 42.75 Cr | 79.63 Cr | 32.76 Cr | 0 |
| Working Capital Loans- Sec | 42.75 Cr | 79.63 Cr | 32.76 Cr | 0 |
| Short Term Provisions | 69.23 Cr | 54.39 Cr | 40.49 Cr | 0 |
| Provision for Tax | 61.89 Cr | 46.26 Cr | 37.1 Cr | 0 |
| Total Current Liabilities | 575.29 Cr | 502.52 Cr | 597.1 Cr | 0 |
| Total Liabilities | 2024.19 Cr | 2068.39 Cr | 2281.5 Cr | 0 |
| Gross Block | 762.84 Cr | 995.24 Cr | 1236.94 Cr | 0 |
| Less: Accumulated Depreciation | 202.2 Cr | 243.43 Cr | 303.81 Cr | 0 |
| Net Block | 560.64 Cr | 751.81 Cr | 933.13 Cr | 0 |
| Capital Work in Progress | 102.03 Cr | 81.4 Cr | 99.83 Cr | 0 |
| Non Current Investments | 0 | 17.41 Cr | 17.41 Cr | 0 |
| Long Term Investment | 0 | 17.41 Cr | 17.41 Cr | 0 |
| Unquoted | 0 | 17.41 Cr | 17.41 Cr | 0 |
| Long Term Loans & Advances | 6.14 Cr | 9.52 Cr | 23.62 Cr | 0 |
| Other Non Current Assets | 209.5 Cr | 233.36 Cr | 49.6 Cr | 0 |
| Total Non-Current Assets | 881.48 Cr | 1101.74 Cr | 1124.63 Cr | 0 |
| Currents Investments | 2.37 Cr | 2.56 Cr | 2.88 Cr | 0 |
| Unquoted | 0 | 17.41 Cr | 17.41 Cr | 0 |
| Inventories | 409.89 Cr | 325.52 Cr | 424.84 Cr | 0 |
| Raw Materials | 243.26 Cr | 134.08 Cr | 193.55 Cr | 0 |
| Work-in Progress | 59.7 Cr | 61.85 Cr | 44.85 Cr | 0 |
| Finished Goods | 47.52 Cr | 59.66 Cr | 116.6 Cr | 0 |
| Stores and Spare | 14.18 Cr | 19.89 Cr | 21.49 Cr | 0 |
| Sundry Debtors | 469.8 Cr | 505.28 Cr | 471.23 Cr | 0 |
| Debtors more than Six months | 20.12 Cr | 10.23 Cr | 6.01 Cr | 0 |
| Debtors Others | 451.07 Cr | 496.46 Cr | 466.87 Cr | 0 |
| Cash and Bank | 139.99 Cr | 21.83 Cr | 142.89 Cr | 0 |
| Cash in hand | 42 Lk | 53 Lk | 88 Lk | 0 |
| Balances at Bank | 139.57 Cr | 21.3 Cr | 142.01 Cr | 0 |
| Other Current Assets | 30.99 Cr | 29.86 Cr | 24.91 Cr | 0 |
| Interest accrued and or due on loans | 3.42 Cr | 91 Lk | 3.12 Cr | 0 |
| Prepaid Expenses | 7.9 Cr | 8.21 Cr | 13.43 Cr | 0 |
| Short Term Loans and Advances | 89.67 Cr | 81.6 Cr | 90.12 Cr | 0 |
| Advances recoverable in cash or in kind | 5.77 Cr | 9.1 Cr | 8.31 Cr | 0 |
| Advance income tax and TDS | 62.8 Cr | 48.01 Cr | 43.86 Cr | 0 |
| Total Current Assets | 1142.71 Cr | 966.65 Cr | 1156.87 Cr | 0 |
| Net Current Assets (Including Current Investments) | 567.42 Cr | 464.13 Cr | 559.77 Cr | 0 |
| Total Assets | 2024.19 Cr | 2068.39 Cr | 2281.5 Cr | 0 |
| Contingent Liabilities | 18 Lk | 5.35 Cr | 6.08 Cr | 0 |
| Total Debt | 42.75 Cr | 79.63 Cr | 32.76 Cr | 0 |
| Book Value | 237.15 | 256.81 | 0 | |
| Adjusted Book Value | 237.15 | 256.81 | 274.49 |
STANDALONE BALANCE SHEET FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 58.71 Cr | 58.71 Cr | 58.71 Cr | 58.71 Cr |
| Equity - Authorised | 80 Cr | 80 Cr | 80 Cr | 80 Cr |
| Equity - Issued | 58.71 Cr | 58.71 Cr | 58.71 Cr | 58.71 Cr |
| Equity Paid Up | 58.71 Cr | 58.71 Cr | 58.71 Cr | 58.71 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | 1201.72 Cr | 1331.56 Cr | 1447.84 Cr | 1552.62 Cr |
| Securities Premium | 225.72 Cr | 225.72 Cr | 225.72 Cr | 225.72 Cr |
| Capital Reserves | 10.76 Cr | 10.76 Cr | 10.76 Cr | 10.76 Cr |
| Profit & Loss Account Balance | 971.31 Cr | 1101.75 Cr | 1218.23 Cr | 1324.3 Cr |
| Reserve excluding Revaluation Reserve | 1201.72 Cr | 1331.56 Cr | 1447.84 Cr | 1552.62 Cr |
| Shareholder's Funds | 1260.43 Cr | 1390.27 Cr | 1506.55 Cr | 1611.33 Cr |
| Deferred Tax Assets / Liabilities | 53.22 Cr | 53.18 Cr | 56.36 Cr | 66.14 Cr |
| Deferred Tax Assets | 2.54 Cr | 2.91 Cr | 3.97 Cr | 4.56 Cr |
| Deferred Tax Liability | 55.76 Cr | 56.09 Cr | 60.33 Cr | 70.7 Cr |
| Other Long Term Liabilities | 2.21 Cr | 43 Lk | 14 Lk | 4 Lk |
| Long Term Provisions | 3.68 Cr | 3.01 Cr | 1.65 Cr | 6.71 Cr |
| Total Non-Current Liabilities | 59.11 Cr | 56.62 Cr | 58.15 Cr | 72.89 Cr |
| Trade Payables | 238.83 Cr | 409.29 Cr | 314.22 Cr | 469.18 Cr |
| Sundry Creditors | 238.83 Cr | 409.29 Cr | 314.22 Cr | 469.18 Cr |
| Other Current Liabilities | 41 Cr | 54.02 Cr | 53.93 Cr | 54.42 Cr |
| Advances received from customers | 4.04 Cr | 14.07 Cr | 7.44 Cr | 8.85 Cr |
| Short Term Borrowings | 0 | 42.75 Cr | 79.63 Cr | 32.76 Cr |
| Secured ST Loans repayable on Demands | 0 | 42.75 Cr | 79.63 Cr | 32.76 Cr |
| Working Capital Loans- Sec | 0 | 42.75 Cr | 79.63 Cr | 32.76 Cr |
| Short Term Provisions | 152.97 Cr | 69.23 Cr | 54.39 Cr | 40.49 Cr |
| Provision for Tax | 146.91 Cr | 61.89 Cr | 46.26 Cr | 37.1 Cr |
| Total Current Liabilities | 432.8 Cr | 575.29 Cr | 502.17 Cr | 596.85 Cr |
| Total Liabilities | 1752.34 Cr | 2022.18 Cr | 2066.87 Cr | 2281.07 Cr |
| Gross Block | 677.69 Cr | 762.84 Cr | 994.71 Cr | 1236.41 Cr |
| Less: Accumulated Depreciation | 165.33 Cr | 202.2 Cr | 243.4 Cr | 303.72 Cr |
| Net Block | 512.36 Cr | 560.64 Cr | 751.31 Cr | 932.69 Cr |
| Capital Work in Progress | 48.27 Cr | 102.03 Cr | 81.4 Cr | 99.83 Cr |
| Non Current Investments | 0 | 10 Lk | 17.71 Cr | 17.71 Cr |
| Long Term Investment | 0 | 10 Lk | 17.71 Cr | 17.71 Cr |
| Unquoted | 0 | 10 Lk | 17.71 Cr | 17.71 Cr |
| Long Term Loans & Advances | 1.6 Cr | 10.77 Cr | 9.52 Cr | 23.62 Cr |
| Other Non Current Assets | 25.57 Cr | 204.87 Cr | 233.36 Cr | 49.6 Cr |
| Total Non-Current Assets | 587.8 Cr | 881.58 Cr | 1101.54 Cr | 1124.49 Cr |
| Currents Investments | 1.22 Cr | 2.37 Cr | 2.56 Cr | 2.88 Cr |
| Unquoted | 0 | 10 Lk | 17.71 Cr | 17.71 Cr |
| Inventories | 295.15 Cr | 409.89 Cr | 325.52 Cr | 424.84 Cr |
| Raw Materials | 181.75 Cr | 243.26 Cr | 134.08 Cr | 193.55 Cr |
| Work-in Progress | 35.73 Cr | 59.7 Cr | 61.85 Cr | 44.85 Cr |
| Finished Goods | 39.84 Cr | 47.52 Cr | 59.66 Cr | 116.6 Cr |
| Stores and Spare | 14.29 Cr | 14.18 Cr | 19.89 Cr | 21.49 Cr |
| Sundry Debtors | 300.31 Cr | 469.8 Cr | 505.28 Cr | 471.23 Cr |
| Debtors more than Six months | 0 | 20.12 Cr | 10.23 Cr | 6.01 Cr |
| Debtors Others | 300.43 Cr | 451.07 Cr | 496.46 Cr | 466.87 Cr |
| Cash and Bank | 364.74 Cr | 137.88 Cr | 20.9 Cr | 142.62 Cr |
| Cash in hand | 1.43 Cr | 42 Lk | 53 Lk | 88 Lk |
| Balances at Bank | 363.31 Cr | 137.46 Cr | 20.37 Cr | 141.74 Cr |
| Other Current Assets | 38.52 Cr | 30.99 Cr | 29.83 Cr | 24.91 Cr |
| Interest accrued and or due on loans | 4.7 Cr | 3.42 Cr | 89 Lk | 3.12 Cr |
| Prepaid Expenses | 5.07 Cr | 7.9 Cr | 8.2 Cr | 13.43 Cr |
| Short Term Loans and Advances | 164.6 Cr | 89.67 Cr | 81.24 Cr | 90.1 Cr |
| Advances recoverable in cash or in kind | 17.72 Cr | 5.77 Cr | 8.74 Cr | 8.29 Cr |
| Advance income tax and TDS | 142.25 Cr | 62.8 Cr | 48.01 Cr | 43.86 Cr |
| Total Current Assets | 1164.54 Cr | 1140.6 Cr | 965.33 Cr | 1156.58 Cr |
| Net Current Assets (Including Current Investments) | 731.74 Cr | 565.31 Cr | 463.16 Cr | 559.73 Cr |
| Total Assets | 1752.34 Cr | 2022.18 Cr | 2066.87 Cr | 2281.07 Cr |
| Contingent Liabilities | 52 Lk | 18 Lk | 5.35 Cr | 6.08 Cr |
| Total Debt | 0 | 42.75 Cr | 79.63 Cr | 32.76 Cr |
| Book Value | 214.69 | 236.8 | 256.61 | 0 |
| Adjusted Book Value | 214.69 | 236.8 | 256.61 | 274.46 |
FINANCIAL RATIOS (CONSOLIDATED) FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 28.56 | 23.7 | 22.9 | |
| CEPS(Rs) | 35.93 | 31.56 | 33.61 | |
| DPS(Rs) | 4 | 4 | 5 | |
| Book NAV/Share(Rs) | 237.15 | 256.81 | 274.49 | |
| Tax Rate(%) | 25.43 | 26.24 | 26 | |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 11.83 | 10.18 | 10.81 | |
| EBIT Margin(%) | 10.67 | 9.25 | 9.27 | |
| Pre Tax Margin(%) | 10.3 | 8.51 | 8.52 | |
| PAT Margin (%) | 7.68 | 6.28 | 6.3 | |
| Cash Profit Margin (%) | 9.66 | 8.36 | 9.25 | |
| Performance Ratios | ||||
| ROA(%) | 8.28 | 6.8 | 6.18 | |
| ROE(%) | 12.04 | 9.6 | 8.62 | |
| ROCE(%) | 16.25 | 13.57 | 12.24 | |
| Asset Turnover(x) | 1.08 | 1.08 | 0.98 | |
| Sales/Fixed Asset(x) | 2.86 | 2.52 | 1.91 | |
| Working Capital/Sales(x) | 3.85 | 4.78 | 3.81 | |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.35 | 0.4 | 0.52 | |
| Receivable days | 78.51 | 80.26 | 83.56 | |
| Inventory Days | 68.5 | 60.53 | 64.21 | |
| Payable days | 95.12 | 85.35 | 102.35 | |
| Valuation Parameters | ||||
| PER(x) | 12.39 | 11.94 | 15.79 | |
| PCE(x) | 9.85 | 8.96 | 10.75 | |
| Price/Book(x) | 1.49 | 1.1 | 1.32 | |
| Yield(%) | 1.13 | 1.41 | 1.38 | |
| EV/Net Sales(x) | 0.91 | 0.78 | 0.94 | |
| EV/Core EBITDA(x) | 6.82 | 6.84 | 7.72 | |
| EV/EBIT(x) | 8.49 | 8.38 | 10.18 | |
| EV/CE(x) | 0.98 | 0.83 | 1.22 | |
| M Cap / Sales | 0.95 | 0.75 | 1 | |
| Growth Ratio | ||||
| Net Sales Growth(%) | 0 | 1.52 | -3.8 | |
| Core EBITDA Growth(%) | 0 | -13.45 | 3.73 | |
| EBIT Growth(%) | 0 | -12.02 | -3.59 | |
| PAT Growth(%) | 0 | -17.02 | -3.39 | |
| EPS Growth(%) | 0 | -17.02 | -3.38 | |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.03 | 0.05 | 0.02 | |
| Current Ratio(x) | 1.99 | 1.92 | 1.94 | |
| Quick Ratio(x) | 1.27 | 1.28 | 1.23 | |
| Interest Cover(x) | 28.12 | 12.45 | 12.28 | |
| Total Debt/Mcap(x) | 0.02 | 0.05 | 0.02 | |
FINANCIAL RATIOS (STANDALONE) FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 75.72 | 28.22 | 23.84 | 23.07 |
| CEPS(Rs) | 82.35 | 35.59 | 31.7 | 33.77 |
| DPS(Rs) | 6 | 4 | 4 | 5 |
| Book NAV/Share(Rs) | 214.69 | 236.8 | 256.61 | 274.46 |
| Tax Rate(%) | 22.2 | 25.66 | 26.13 | 25.85 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 30.09 | 11.73 | 10.22 | 10.86 |
| EBIT Margin(%) | 29.35 | 10.58 | 9.29 | 9.32 |
| Pre Tax Margin(%) | 29.05 | 10.2 | 8.55 | 8.56 |
| PAT Margin (%) | 22.6 | 7.59 | 6.31 | 6.35 |
| Cash Profit Margin (%) | 24.58 | 9.57 | 8.39 | 9.3 |
| Performance Ratios | ||||
| ROA(%) | 28.69 | 8.78 | 6.85 | 6.23 |
| ROE(%) | 43.06 | 12.5 | 9.66 | 8.69 |
| ROCE(%) | 54.2 | 17.16 | 13.64 | 12.3 |
| Asset Turnover(x) | 1.27 | 1.16 | 1.08 | 0.98 |
| Sales/Fixed Asset(x) | 3.09 | 3.03 | 2.52 | 1.91 |
| Working Capital/Sales(x) | 2.69 | 3.86 | 4.79 | 3.81 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.32 | 0.33 | 0.4 | 0.52 |
| Receivable days | 53.14 | 64.35 | 80.26 | 83.56 |
| Inventory Days | 44.78 | 58.91 | 60.53 | 64.21 |
| Payable days | 54.31 | 75.31 | 85.35 | 102.35 |
| Valuation Parameters | ||||
| PER(x) | 7.27 | 12.54 | 11.87 | 15.67 |
| PCE(x) | 6.69 | 9.94 | 8.92 | 10.7 |
| Price/Book(x) | 2.56 | 1.49 | 1.1 | 1.32 |
| Yield(%) | 1.09 | 1.13 | 1.41 | 1.38 |
| EV/Net Sales(x) | 1.46 | 0.91 | 0.78 | 0.94 |
| EV/Core EBITDA(x) | 4.65 | 6.87 | 6.82 | 7.69 |
| EV/EBIT(x) | 4.97 | 8.58 | 8.35 | 10.13 |
| EV/CE(x) | 1.64 | 0.98 | 0.83 | 1.22 |
| M Cap / Sales | 1.64 | 0.95 | 0.75 | 1 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 3.83 | 11.03 | 1.52 | -3.8 |
| Core EBITDA Growth(%) | 4.45 | -53.21 | -12.57 | 3.77 |
| EBIT Growth(%) | 4.16 | -59.96 | -10.89 | -3.51 |
| PAT Growth(%) | 23.05 | -62.74 | -15.5 | -3.26 |
| EPS Growth(%) | 19.23 | -62.74 | -15.5 | -3.26 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0 | 0.03 | 0.05 | 0.02 |
| Current Ratio(x) | 2.69 | 1.98 | 1.92 | 1.94 |
| Quick Ratio(x) | 2.01 | 1.27 | 1.27 | 1.23 |
| Interest Cover(x) | 99.01 | 27.88 | 12.51 | 12.34 |
| Total Debt/Mcap(x) | 0 | 0.02 | 0.05 | 0.02 |
SHARE HOLDING PATTERN FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Date | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 43.69 | 43.69 | 43.69 | 43.69 | 48.19 | 48.19 | 48.19 | 48.19 | 48.19 | 48.19 |
| FII % | 3.14 | 2.50 | 2.41 | 2.37 | 2.43 | 2.33 | 2.18 | 1.40 | 1.39 | 1.63 |
| DII % | 0.02 | 0.03 | 0.03 | 0.14 | 0.21 | 0.30 | 0.30 | 0.21 | 0.00 | 0.05 |
| Public % | 53.13 | 53.77 | 53.83 | 53.78 | 49.15 | 49.13 | 49.27 | 50.11 | 50.34 | 50.11 |
PEER COMPARISON FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
CORPORATE ACTIONS FOR IOL CHEMICALS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 30-Jul-2024 | Board Meeting - Quarterly Results | 09-Aug-2024 |
| BSE 14-May-2024 | Book Closure - A.G.M. | 17-Aug-2024 23-Aug-2024 |
| BSE 14-May-2024 | AGM - A.G.M. | 23-Aug-2024 23-Aug-2024 |
| BSE 06-May-2024 | Board Meeting - Audited Results | 14-May-2024 |
| BSE 16-Feb-2024 | Dividend - Rs.5.0000 per share(50%)Interim Dividend | |
| BSE 29-Jan-2024 | Board Meeting - Quarterly Results & Interim Dividend | 06-Feb-2024 |
| BSE 30-Oct-2023 | Board Meeting - Quarterly Results | 08-Nov-2023 |
| BSE 03-Aug-2023 | Board Meeting - Quarterly Results | 09-Aug-2023 |
| BSE 28-Apr-2023 | Book Closure - A.G.M. | 04-Aug-2023 10-Aug-2023 |
| BSE 28-Apr-2023 | AGM - A.G.M. | 10-Aug-2023 10-Aug-2023 |
| BSE 21-Apr-2023 | Board Meeting - Audited Results & Quarterly Results | 28-Apr-2023 |
| BSE 17-Feb-2023 | Dividend - Rs.4.0000 per share(40%)Interim Dividend | |
| BSE 01-Feb-2023 | Board Meeting - Interim Dividend & Audited Results | 07-Feb-2023 |
| BSE 03-Nov-2022 | Board Meeting - Quarterly Results | 14-Nov-2022 |
| BSE 29-Jul-2022 | Board Meeting - Quarterly Results | 09-Aug-2022 |
| BSE 31-May-2022 | Book Closure - A.G.M. | 20-Aug-2022 26-Aug-2022 |
| BSE 31-May-2022 | AGM - A.G.M. | 26-Aug-2022 26-Aug-2022 |
| BSE 23-May-2022 | Board Meeting - Quarterly Results | 30-May-2022 |
| BSE 15-Feb-2022 | Dividend - Rs.4.0000 per share(40%)Interim Dividend | |
| BSE 28-Jan-2022 | Board Meeting - Quarterly Results & Interim Dividend | 04-Feb-2022 |
| BSE 03-Nov-2021 | Board Meeting - Quarterly Results | 12-Nov-2021 |
CORPORATE ANNOUNCEMENTS FOR IOL CHEMICALS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 30-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Credit Rating Reaffirmation of Credit Rating |
| BSE 28-Oct-2024 | Outcome FILE | Board Meeting Outcome for Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Pursuant to the provisions of the Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations") we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e. 28th October 2024 inter-alia approved the following:1. Appointment of Ms Rajni Jha (DIN: 10818947) as an Additional and Independent Director of the Company for a term of three years with effect from 28th October 2024 subject to approval of Members of the Company.2. Approved the Postal Ballot Notice to seek the approval of the shareholders through Postal Ballot for appointment of Ms Rajni Jha as Independent Director of the Company. |
| BSE 28-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Directorate Appointment of Ms Rajni Jha as an Additional and Independent Director of the Company |
| BSE 05-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 for the quarter ended 30th September 2024 |
| BSE 05-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Detail of issue of Confirmation Letter in lieu of lost share certificates |
| BSE 27-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of lost share certificate |
| BSE 25-Sep-2024 | Intimation FILE | Closure of Trading Window Notice of closure of Trading Window |
| BSE 24-Sep-2024 | General Announcements FILE | Dispatch Of Reminder Letter To Shareholders To Update KYC Dispatch of reminder letter to shareholders to update KYC |
| BSE 23-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Schedule of Analyst / Investor Meet |
| BSE 18-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Intimation of resignation of Chief Executive Officer of the Company |
| BSE 09-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of lost share certificates |
| BSE 06-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of lost share certificate |
| BSE 28-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Detail of issue of Confirmation Letter in lieu of lost share certificates |
| BSE 23-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting Results and Scrutinizers Report of 37th Annual General Meeting |
| BSE 23-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Proceedings of 37th Annual General Meeting |
| BSE 20-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earning Call Transcript |
| BSE 13-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q1-FY2025 |
| BSE 12-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation Q1 FY2025 |
| BSE 12-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of Newspaper publication of Un-audited Financial Results for the quarter ended 30th June 2024 |
| BSE 09-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release: Financial Results for quarter ended 30th June 2024 |
| BSE 09-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Completion of 2nd and final term of Dr Sandhya Mehta as Independent Director of the Company |
| BSE 09-Aug-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of The Board Meeting Outcome of the Board Meeting |
| BSE 09-Aug-2024 | Outcome FILE | Un-Audited Financial Results For The Quarter Ended 30Th June 2024 Un-Audited Financial Results for the quarter ended 30th June 2024 |
| BSE 08-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Schedule of analyst / investor conference call - Q1-FY2025 |
| BSE 06-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of issue of Confirmation letter in lieu of lost share certificates |
| BSE 02-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Notice published in Newspapers |
| BSE 01-Aug-2024 | General Announcements FILE | Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report |
| BSE 01-Aug-2024 | General Announcements FILE | Notice Of 37Th Annual General Meeting (AGM) Of The Company Notice of 37th Annual General Meeting of the Company |
| BSE 01-Aug-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Integrated Annual Report for FY 2023-24 and Notice of 37th Annual General Meeting |
| BSE 30-Jul-2024 | Intimation FILE | Board Meeting Intimation for Notice Of The Board Meeting IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Financial Results of the Company for the Quarter ended 30th June 2024 |
INSIDER TRADING FOR IOL CHEMICALS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Insider trading details found | |||
BULK BLOCK DEALS FOR IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 18-Feb-2025 | INTERIM DIVIDEND | 4 |
| 16-Feb-2024 | INTERIM DIVIDEND | 5 |
| 17-Feb-2023 | INTERIM DIVIDEND | 4 |
| 15-Feb-2022 | INTERIM DIVIDEND | 4 |
| 08-Sep-2021 | DIVIDEND | 2 |
| 17-Nov-2020 | INTERIM DIVIDEND | 4 |
SPLIT / BONUS BY IOL CHEMICALS AND PHARMACEUTICALS LIMITED
| Ex Date | Type | Detail |
|---|---|---|
| 11-Mar-2025 | SPLIT | Rs 10 to Rs 2 |
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
